A rising prostate-specific antigen (PSA) level after prostate cancer treatment can create an unsettling clinical crossroads. The patient may feel well. Imaging may show no evidence of metastatic disease. Yet the laboratory results suggest that the cancer has returned.

For the oncology team, the challenge is deciding which patients need additional treatment, when that treatment should begin, and whether a more intensive approach will ultimately help them live longer.

Updated findings from the phase 3 EMBARK trial offer important evidence for patients with high-risk biochemical recurrence following definitive treatment for prostate cancer.

Moving Beyond Metastasis-Free Survival
EMBARK enrolled patients with nonmetastatic, hormone-sensitive prostate cancer who experienced high-risk biochemical recurrence after radical prostatectomy, radiotherapy, or both. Participants had a PSA doubling time of nine months or less, identifying a population at elevated risk of progression.

Patients were randomized to receive enzalutamide plus leuprolide, leuprolide alone, or enzalutamide monotherapy.

Earlier findings established that enzalutamide-containing treatment significantly improved metastasis-free survival, but would delaying metastasis translate into longer overall survival? The updated analysis provides a meaningful answer.

At eight years, estimated overall survival was 78.9% among patients receiving enzalutamide plus leuprolide, compared with 69.5% among those receiving leuprolide alone. The combination was associated with a 40% relative reduction in the risk of death (hazard ratio [HR], 0.60; 95% CI, 0.44-0.80; P<.001).

Enzalutamide monotherapy demonstrated an eight-year overall survival rate of 73.1%, but the difference compared with leuprolide alone was not statistically significant (HR, 0.83; 95% CI, 0.63-1.10; P=.19).

The distinction matters. Different treatment strategies involving the same agent do not necessarily produce equivalent survival outcomes.

Identifying Patients Most Likely to Benefit
The EMBARK population represented a specific group of patients with high-risk biochemical recurrence, rather than all individuals experiencing a PSA increase after treatment.

Not every detectable PSA warrants immediate treatment intensification. Decisions must account for disease characteristics, prior treatment, comorbidities, life expectancy, and patient preferences.

For patients meeting high-risk criteria, however, the updated survival findings provide stronger evidence supporting combination treatment.

They also offer a more meaningful foundation for conversations with patients who may be weighing the potential benefits of additional therapy against its adverse effects.

What the Findings Mean Across the Care Team
Treatment intensification introduces responsibilities that extend beyond selecting a regimen.

Androgen deprivation and androgen receptor pathway inhibition can affect fatigue, sexual health, cognitive function, cardiovascular and metabolic health, and overall quality of life. Long-term monitoring and supportive care remain essential.

Pharmacists play an important role in medication reconciliation, identifying potential drug interactions, and supporting adherence. Nurses and navigators are often central to recognizing treatment-related concerns, reinforcing patient education, and helping individuals remain engaged in follow-up care.

The psychological dimension of biochemical recurrence also deserves attention. Patients may struggle to understand why additional treatment is necessary when they have no symptoms and no visible metastatic disease.

Clear communication about recurrence risk, treatment goals, and the distinction between biochemical and radiographic progression can help make these decisions more understandable.

A More Meaningful Measure of Treatment Benefit
The updated EMBARK findings represent an important development because they connect treatment intensification with an overall survival benefit, rather than relying exclusively on intermediate endpoints.

They do not eliminate the need for individualized decision-making. Instead, they provide stronger evidence to guide it.

For multidisciplinary oncology teams, the message is both clinical and practical: Recognizing high-risk recurrence, understanding which patients may benefit from combination treatment, and supporting those patients throughout therapy are all essential components of effective care.

Source
Shore ND, de Almeida Luz M, De Giorgi U, et al. Improved survival with enzalutamide in biochemically recurrent prostate cancer. N Engl J Med. 2026;394:563-575.